| Dec'19 | Nov'18 | Nov'17 | Nov'16 | Nov'15 | Nov'14 | Nov'13 | Nov'12 | Nov'11 | Nov'10 |
|---|---|---|---|---|---|---|---|---|---|
CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||||
NET LOSS (INCOME) | |||||||||
-26,041 | -19,104 | -12,367 | - | - | - | - | - | - | - |
Adjustments required to reconcile net loss to net cash used in operating activities: | |||||||||
Net loss | |||||||||
- | - | - | -11,113 | -4,461 | -5,504 | -5,539 | -4,998 | -72 | -36 |
Adjustments required to reconcile net loss to net cash used in operating activities: | |||||||||
Write-off of website development costs | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 15 |
Stock-based compensation | |||||||||
3,057 | 4,364 | 3,364 | 2,869 | 803 | 2,487 | 2,795 | 2,976 | 0 | - |
Stock based compensation to First Choice | |||||||||
2,641 | - | - | - | - | - | - | - | - | - |
Capital gain, net | |||||||||
29 | - | - | - | - | - | - | - | - | - |
Share in losses of associated company | |||||||||
- | -731 | -1,214 | -123 | 0 | - | - | - | - | - |
Loss from extinguishment of a convertible loan | |||||||||
- | - | - | -229 | 0 | - | - | - | - | - |
Depreciation and amortization expenses | |||||||||
3,806 | 2,624 | 2,598 | 2,923 | 1,991 | - | - | - | - | - |
Depreciation and amortization expenses | |||||||||
- | - | - | - | - | 5 | 3 | 1 | 0 | - |
Change in fair value of warrants and embedded derivatives | |||||||||
- | -26 | 826 | -187 | 1,375 | 180 | 133 | 0 | - | - |
Change in fair value of convertible bonds | |||||||||
- | - | 192 | 84 | 1,221 | 0 | - | - | - | - |
Net changes in operating leases | |||||||||
-339 | - | - | - | - | - | - | - | - | - |
Interest expenses accrued on loans and convertible loans (including amortization of beneficial conversion feature) | |||||||||
387 | 2,564 | 1,110 | 283 | 502 | 1,086 | 172 | 0 | - | - |
Changes in operating assets and liabilities: | |||||||||
Increase in accounts receivable | |||||||||
5,308 | 2,901 | -33 | 54 | 731 | 0 | - | - | - | - |
Increase in inventory | |||||||||
414 | 931 | 265 | 101 | 87 | 0 | - | - | - | - |
Increase in other assets | |||||||||
46 | 19 | 3 | 17 | 22 | 0 | - | - | - | - |
It represents increase decrease in exchange differences on inter company balances. | |||||||||
-214 | - | - | - | - | - | - | - | - | - |
Decrease (increase) in prepaid expenses, other accounts receivable | |||||||||
112 | -380 | 107 | -136 | 1,083 | 74 | 8 | 27 | 0 | 0 |
Increase in accrued professional fees | |||||||||
- | - | - | - | - | - | - | - | - | 0 |
Change in related parties, net | |||||||||
- | -532 | -583 | 0 | - | - | - | 6 | 35 | 0 |
Increase (decrease) in accounts payable | |||||||||
4,626 | -796 | -933 | 1,079 | 1,497 | 1,016 | 2 | 91 | 37 | 5 |
Net gain on remeasurement of previously equity interest in Atvio and CureCell to acquisition date fair value. | |||||||||
- | 4,509 | 0 | - | - | - | - | - | - | - |
Stock-based compensation related to options and shares granted to service pproviders | |||||||||
- | - | - | - | - | - | 322 | - | - | - |
Increase in retirement benefits obligation | |||||||||
- | - | - | - | - | - | 2 | - | 0 | - |
Shares to be issued for services rendered | |||||||||
- | - | - | - | - | - | - | 509 | 0 | - |
Stock-based compensation related to options granted to consultants | |||||||||
- | - | - | - | - | - | - | 242 | 0 | - |
Increase (decrease) in employee and related payables | |||||||||
- | - | - | - | - | - | - | 1 | - | - |
Decrease in accrued expenses and other payables | |||||||||
271 | 428 | 92 | 399 | 538 | -11 | 312 | 68 | 0 | - |
Increase (decrease) in employee and related payables | |||||||||
474 | -105 | 1,142 | 352 | 353 | 472 | 79 | 75 | 0 | - |
Increase in deferred income | |||||||||
- | - | 1,044 | 53 | 1,039 | 0 | - | - | - | - |
Increase in contract liabilities, mainly related party | |||||||||
3,536 | 1,309 | - | - | - | - | - | - | - | - |
Increase (decrease) in advance payments and receivables on account of grant, net | |||||||||
-247 | -193 | 2,156 | 499 | 451 | -726 | 0 | - | - | - |
Increase (decrease) in deferred taxes | |||||||||
304 | 982 | -1,310 | -1,546 | -900 | 0 | - | - | - | - |
Net cash used in operating activities | |||||||||
-13,220 | -15,682 | -3,833 | -3,783 | -2,706 | -1,429 | -1,989 | -1,051 | -0 | -14 |
CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||||
Long-term deposits | |||||||||
228 | 15 | 0 | - | - | - | - | - | - | - |
Increase in loan to JV with a related party | |||||||||
-1,500 | -1,000 | 0 | - | - | - | - | - | - | - |
Sale of property and equipment | |||||||||
79 | - | - | - | - | - | - | - | - | - |
Purchase of property and equipment | |||||||||
12,129 | 5,556 | 975 | 1,425 | 982 | 5 | 7 | 9 | 0 | - |
Investment in short term deposits | |||||||||
- | - | 2,429 | 111 | 0 | - | - | - | - | - |
Restricted cash | |||||||||
- | - | - | - | 5 | 0 | - | - | - | - |
Website development costs | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Short term investments and deposits | |||||||||
- | - | - | - | - | -10 | 0 | 10 | 0 | - |
Acquisition of CureCell, net of cash acquired | |||||||||
- | -58 | 0 | - | -305 | 0 | - | - | - | - |
Acquisition of Atvio , net of cash acquired. | |||||||||
- | 245 | 0 | - | - | - | - | - | - | - |
Short term investments and deposits | |||||||||
- | - | - | - | -250 | - | 0 | - | - | - |
Amounts funded in respect of retirement benefits obligation | |||||||||
- | - | - | - | - | 3 | 2 | 1 | 0 | - |
Net cash provided by (used in) investing activities | |||||||||
-13,778 | -6,268 | -3,404 | -1,536 | -932 | 2 | -10 | -20 | 0 | 0 |
CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||||
Increase in redeemable non-controlling interests received from GPP | |||||||||
13,200 | - | - | - | - | - | - | - | - | - |
Proceeds from issuance of convertible loans (net of transaction costs) | |||||||||
11,400 | 1,912 | 5,899 | 1,599 | 950 | 1,750 | 250 | - | - | - |
Repayment of convertible loans and convertible bonds | |||||||||
- | 177 | 4,051 | 0 | - | - | - | - | - | - |
Short-term line of credit | |||||||||
- | - | - | - | -14 | 14 | 0 | - | - | - |
Short-term line of credit | |||||||||
- | - | -21 | 21 | - | - | - | - | - | - |
Proceeds from issuance of shares and warrants (net of transaction costs) | |||||||||
- | 17,392 | 5,297 | 1,488 | 4,203 | 922 | 1,800 | 1,071 | 0 | 0 |
Represents amount of redeemable non-controlling interest. | |||||||||
- | 14,058 | 2,349 | 0 | - | - | - | - | - | - |
Proceeds from receipts on account of shares to be allotted. | |||||||||
- | 2,252 | 0 | - | - | - | - | - | - | - |
Repayment of short and long-term debt | |||||||||
772 | 377 | 1,108 | - | - | - | - | - | - | - |
Proceeds from issuance of warrants into shares and warrants | |||||||||
- | - | - | - | - | 50 | 0 | - | - | - |
Proceeds from exercise of stock options | |||||||||
- | - | - | - | - | 1 | 0 | - | - | - |
Proceeds from issuance of loans payable | |||||||||
270 | - | - | - | 3,946 | 0 | - | - | - | - |
Other financing activities | |||||||||
- | - | - | 1,121 | - | - | - | 0 | - | - |
Repayment of short and long-term debt | |||||||||
- | - | - | 2,106 | 2,419 | 0 | - | - | - | - |
Net cash provided by financing activities | |||||||||
24,098 | 35,060 | 8,365 | 2,123 | 6,666 | 2,737 | 2,050 | 1,071 | 0 | 0 |
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | |||||||||
-2,900 | 13,110 | - | - | - | - | - | - | - | - |
SUPPLEMENTAL NON-CASH FINANCING AND INVESTING ACTIVITIES | |||||||||
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | |||||||||
-58 | -173 | - | - | - | - | - | - | - | - |
NET CHANGE IN CASH AND CASH EQUIVALENTS | |||||||||
- | - | 1,128 | -3,196 | 3,028 | 1,310 | 50 | -0 | -0 | -14 |
EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH | |||||||||
- | - | 1,497 | -81 | -174 | -47 | 0 | - | - | - |
SUPPLEMENTAL NON-CASH FINANCING ACTIVITIES | |||||||||
Interest Paid, Excluding Capitalized Interest, Operating Activities | |||||||||
157 | 134 | - | - | - | - | - | - | - | - |
Income Taxes Paid | |||||||||
156 | - | - | - | - | - | - | - | - | - |
Non Cash Financing Items [Abstract] | |||||||||
Conversion of loans and bonds (including accrued interest) to common stock and warrants. | |||||||||
- | 7,511 | 1,277 | 1,028 | 0 | 631 | - | - | - | - |
Redeemable non-controlling interest | |||||||||
- | - | - | 21,458 | - | - | - | - | - | - |
Reclassification of redeemable common stock to equity | |||||||||
- | - | - | - | 0 | - | - | - | - | - |
Represents amount of classification of loan receivable into services to be received from CureCell. | |||||||||
- | 836 | 0 | - | - | - | - | - | - | - |
Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction | |||||||||
546 | - | - | - | - | - | - | - | - | - |
Receivable from GPP | |||||||||
- | 6,600 | 0 | - | - | - | - | - | - | - |
Right-of-use assets obtained in exchange for new operation lease liabilities, net | |||||||||
8,229 | - | - | - | - | - | - | - | - | - |
Purchase of property, plant and equipment included in accounts payable | |||||||||
1,584 | - | - | - | - | - | - | - | - | - |
Noncash or Part Noncash Acquisition, Fixed Assets Acquired | |||||||||
355 | 955 | 0 | - | - | - | - | - | - | - |
Interest | |||||||||
- | - | - | - | - | - | - | - | - | 0 |
Income taxes | |||||||||
- | - | - | - | - | - | - | - | - | 0 |
Common stock issued for rended services | |||||||||
- | - | - | - | - | 37 | 0 | - | - | - |
Warrants to be issued to credit providers | |||||||||
- | - | - | - | 208 | 0 | - | - | - | - |
SUPPLEMENTAL INFORMATION ON INTEREST PAID IN CASH | |||||||||
- | - | 903 | 106 | 125 | 0 | - | - | - | - |
Common stock and warrants issued for conversion of loans and accrued interest | |||||||||
- | - | - | - | - | - | 0 | - | - | - |